Gaining MOMENTUM against anaemic myelofibrosis
- PMID: 36709064
- DOI: 10.1016/S0140-6736(23)00171-X
Gaining MOMENTUM against anaemic myelofibrosis
Conflict of interest statement
KI reports speaker's fees from Novartis, Pharma Essentia, Otsuka, Ortho Clinical Diagnostics, Zeria, Takeda, Kyowa-Kirin, Astellas, and Ono; and research funding from Takeda, Sanofi, Ono, Kyowa Kirin, Daiichi Sankyo, Kyokuto, and Hokuyo-Denki. KU declares no competing interests.
Comment on
-
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
